CA2767982A1 - Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers - Google Patents
Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers Download PDFInfo
- Publication number
- CA2767982A1 CA2767982A1 CA2767982A CA2767982A CA2767982A1 CA 2767982 A1 CA2767982 A1 CA 2767982A1 CA 2767982 A CA2767982 A CA 2767982A CA 2767982 A CA2767982 A CA 2767982A CA 2767982 A1 CA2767982 A1 CA 2767982A1
- Authority
- CA
- Canada
- Prior art keywords
- barrier layer
- manifold
- tissue site
- perforations
- providing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004888 barrier function Effects 0.000 title claims abstract description 189
- 238000000034 method Methods 0.000 title claims abstract description 24
- 210000001519 tissue Anatomy 0.000 claims abstract description 84
- 239000012530 fluid Substances 0.000 claims abstract description 60
- 239000000463 material Substances 0.000 claims abstract description 40
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 210000002615 epidermis Anatomy 0.000 claims abstract description 12
- 238000004891 communication Methods 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 239000013003 healing agent Substances 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 210000000416 exudates and transudate Anatomy 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 239000000499 gel Substances 0.000 description 13
- 239000000853 adhesive Substances 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- 239000006260 foam Substances 0.000 description 6
- 229920001971 elastomer Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000002803 maceration Methods 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920006397 acrylic thermoplastic Polymers 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- -1 open-cell Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 229920002943 EPDM rubber Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 229920000181 Ethylene propylene rubber Polymers 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 229920001247 Reticulated foam Polymers 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920002681 hypalon Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000009581 negative-pressure wound therapy Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/91—Suction aspects of the dressing
- A61M1/915—Constructional details of the pressure distribution manifold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/95—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with sensors for exudate composition
-
- A61F13/05—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/92—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
Abstract
Reduced-pressure medical dressings (100), systems, and methods involve a dressing (104) with a first barrier layer (112) that desolidifies when exposed to a fluid - typically a liquid - to form a treatment aperture in the first barrier that is used to deliver reduced pressure to a tissue site. The first barrier layer is formed from a desolidifying material. The system includes a drape (120) covering a second surface of a manifold (110) and a portion of the patient's epidermis (138) to provide a substantially sealed space (118) containing a manifold and the first barrier layer. Other systems, dressings, and methods are also disclosed.
Description
TITLE OF THE INVENTION
REDUCED-PRESSURE DRESSINGS, SYSTEMS, AND METHODS EMPLOYING
DESOLIDIFYING BARRIER LAYERS
RELATED APPLICATION
[0001] The present invention claims the benefit, under 35 USC 119(e), of the filing of U.S. Provisional Patent Application serial number 61/225,604 entitled "Reduced-Pressure Dressings, Systems, and Methods Employing Desolidifying Barrier Layers," filed July 15, 2009, which is incorporated herein by reference for all purposes.
BACKGROUND
REDUCED-PRESSURE DRESSINGS, SYSTEMS, AND METHODS EMPLOYING
DESOLIDIFYING BARRIER LAYERS
RELATED APPLICATION
[0001] The present invention claims the benefit, under 35 USC 119(e), of the filing of U.S. Provisional Patent Application serial number 61/225,604 entitled "Reduced-Pressure Dressings, Systems, and Methods Employing Desolidifying Barrier Layers," filed July 15, 2009, which is incorporated herein by reference for all purposes.
BACKGROUND
[0002] The disclosure relates generally to medical treatment systems, and more particularly, but not by way of limitation, to reduced-pressure dressings, systems, and methods employing desolidifying barrier layers.
[0003] Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site.
The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as "negative pressure wound therapy," "reduced pressure therapy," or "vacuum therapy") provides a number of benefits, which may include faster healing and increased formulation of granulation tissue. Unless otherwise indicated, as used herein, "or"
does not require mutual exclusivity.
SUMMARY
The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as "negative pressure wound therapy," "reduced pressure therapy," or "vacuum therapy") provides a number of benefits, which may include faster healing and increased formulation of granulation tissue. Unless otherwise indicated, as used herein, "or"
does not require mutual exclusivity.
SUMMARY
[0004] Improvements to existing reduced-pressure treatment apparatuses, systems, and methods may be realized by the apparatuses, systems, and methods of the illustrative, non-limiting embodiments herein. According to an illustrative, non-limiting embodiment, a system for providing reduced-pressure therapy to a tissue site of a patient includes a reduced-pressure source for supplying reduced pressure and a manifold having a first, inward-facing surface and a second surface. The manifold is operable to transfer the reduced pressure.
The system includes a first barrier layer covering at least a portion of the first, inward-facing surface of the manifold. The first barrier layer is for placement adjacent the tissue site and the first barrier layer is formed from a desolidifying material. The system also includes a drape for covering the second surface of the manifold and a portion of the patient's epidermis to provide a substantially sealed space containing the manifold and the first barrier layer.
The system includes a first barrier layer covering at least a portion of the first, inward-facing surface of the manifold. The first barrier layer is for placement adjacent the tissue site and the first barrier layer is formed from a desolidifying material. The system also includes a drape for covering the second surface of the manifold and a portion of the patient's epidermis to provide a substantially sealed space containing the manifold and the first barrier layer.
[0005] According to another illustrative, non-limiting embodiment, an apparatus includes a manifold having a first, inward-facing surface and a second surface. The manifold is operable to transfer reduced pressure. The apparatus also includes a first barrier layer covering at least a portion of the first, inward-facing surface of the manifold. The first barrier layer is formed from a desolidifying material.
[0006] According to another illustrative, non-limiting embodiment, a method for providing reduced-pressure therapy to a tissue site of a patient includes applying a dressing to the tissue site. The dressing includes a manifold having a first, inward-facing surface and a second surface, and the manifold is operable to transfer reduced pressure. The dressing also includes a first barrier layer covering at least a portion of the first, inward-facing surface of the manifold. The first barrier layer is formed from a desolidifying material. The method also includes allowing fluid at the tissue site to desolidify at least a portion of the first barrier layer to create a treatment aperture and applying a reduced pressure to the tissue site via the treatment aperture.
[0007] According to another illustrative, non-limiting embodiment, a method of manufacturing an apparatus for providing reduced-pressure therapy to a tissue site of a patient includes providing a manifold having a first, inward-facing surface and a second surface, and providing a first barrier layer formed from a desolidifying material. The method also includes coupling the first barrier layer to the first, inward-facing surface of the manifold.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] FIGURE IA is a schematic, cross-sectional view, with a portion shown as a block diagram, of a reduced-pressure treatment system according to one illustrative, non-limiting embodiment;
[0009] FIGURE 113 is a schematic, cross-sectional view of the dressing shown in FIGURE IA in which a portion of the first barrier layer has desolidified;
[0010] FIGURE 1C is a schematic, plan view of the dressing shown in FIGURE 113 from the perspective of the tissue site;
[0011] FIGURE 2 is a schematic, cross-sectional view of a manifold and a first and second barrier layer shown according to an illustrative, non-limiting embodiment; and
[0012] FIGURE 3 is a schematic, cross-sectional view of a manifold according to an illustrative, non-limiting embodiment, which has a first and second barrier layer in which one of the barrier layers has a plurality of perforations.
DETAILED DESCRIPTION
DETAILED DESCRIPTION
[0013] In the following detailed description of the illustrative, non-limiting embodiments, reference is made to the accompanying drawings that form a part hereof. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.
[0014] Referring now to the drawings and primarily to FIGURES IA through 1C, a reduced-pressure therapy system 100, which includes a reduced-pressure source 102 and a dressing 104, is shown according to an illustrative, non-limiting embodiment.
The dressing 104 includes a manifold 110 and a first barrier layer 112 that is configured to help avoid maceration of intact skin and to encourage epithelialization. The dressing 104 is applied to a tissue site 106, which may include a wound 107, of a patient 108 so that reduced pressure from the reduced-pressure source 102 can be transferred to the tissue site 106 via the dressing 104.
The dressing 104 includes a manifold 110 and a first barrier layer 112 that is configured to help avoid maceration of intact skin and to encourage epithelialization. The dressing 104 is applied to a tissue site 106, which may include a wound 107, of a patient 108 so that reduced pressure from the reduced-pressure source 102 can be transferred to the tissue site 106 via the dressing 104.
[0015] As used herein, "reduced pressure" generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located.
Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site.
Unless otherwise indicated, values of pressure stated herein are gauge pressures. The reduced pressure delivered may be constant or varied (patterned or random) and may be delivered continuously or intermittently. Although the terms "vacuum" and "negative pressure" may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum.
Consistent with the use herein, an increase in reduced pressure or vacuum pressure typically refers to a relative reduction in absolute pressure.
Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site.
Unless otherwise indicated, values of pressure stated herein are gauge pressures. The reduced pressure delivered may be constant or varied (patterned or random) and may be delivered continuously or intermittently. Although the terms "vacuum" and "negative pressure" may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum.
Consistent with the use herein, an increase in reduced pressure or vacuum pressure typically refers to a relative reduction in absolute pressure.
[0016] The tissue site 106 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue.
Treatment of the tissue site 106 may include removal of fluids, e.g., ascites, exudate, or delivery of reduced pressure.
The wound 107 on the tissue site 106 may be due to a variety of causes, including trauma or surgery.
Treatment of the tissue site 106 may include removal of fluids, e.g., ascites, exudate, or delivery of reduced pressure.
The wound 107 on the tissue site 106 may be due to a variety of causes, including trauma or surgery.
[0017] The dressing 104 includes the manifold 110 and the first barrier layer 112. The manifold 110 includes a first, inward-facing (tissue-facing) surface 114 and a second surface 116. The term "manifold" as used herein generally refers to a substance or structure that is provided to assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site 106. The manifold 110 typically includes a plurality of flow channels or pathways that improve distribution of fluids provided to and removed from the tissue site 106 around the manifold 110. The plurality of flow channels may be interconnected. The manifold 110 may be a biocompatible material that is capable of being placed in contact with the tissue site 106 and distributing reduced pressure to the tissue site 106.
Examples of the manifold 110 may include, for example, without limitation, devices that have structural elements arranged to form flow channels, such as, for example, cellular foam, open-cell foam, porous tissue collections, liquids, gels, and foams that include, or cure to include, flow channels. The manifold 110 may be porous and may be made from foam, gauze, felted mat, or any other material suited to a particular biological application. In one embodiment, the manifold 110 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam, such as a GranuFoam material manufactured by Kinetic Concepts, Incorporated of San Antonio, Texas. Other embodiments may include "closed cells." In some situations, the manifold 110 may also be used to distribute fluids, such as medications, antibacterials, growth factors, and various solutions to the tissue site 106. Other layers may be included in or on the manifold 110, such as absorptive materials, wicking materials, hydrophobic materials, and hydrophilic materials.
Examples of the manifold 110 may include, for example, without limitation, devices that have structural elements arranged to form flow channels, such as, for example, cellular foam, open-cell foam, porous tissue collections, liquids, gels, and foams that include, or cure to include, flow channels. The manifold 110 may be porous and may be made from foam, gauze, felted mat, or any other material suited to a particular biological application. In one embodiment, the manifold 110 is a porous foam and includes a plurality of interconnected cells or pores that act as flow channels. The porous foam may be a polyurethane, open-cell, reticulated foam, such as a GranuFoam material manufactured by Kinetic Concepts, Incorporated of San Antonio, Texas. Other embodiments may include "closed cells." In some situations, the manifold 110 may also be used to distribute fluids, such as medications, antibacterials, growth factors, and various solutions to the tissue site 106. Other layers may be included in or on the manifold 110, such as absorptive materials, wicking materials, hydrophobic materials, and hydrophilic materials.
[0018] The dressing 104 also includes the first barrier layer 112 that covers at least a portion of the first, inward-facing surface 114 of the manifold 110. The first barrier layer 112 is disposed adjacent to the tissue site 106 such that the first barrier layer 112 is disposed between the manifold 110 and the tissue site 106. The first barrier layer 112 may be fixedly or non-fixedly attached to the manifold 110. For example, the first barrier layer 112 may simply abut the manifold 110 without the aid of an adhesive or another attachment device. Also, the first barrier layer 112 may be coupled to the manifold 110. As used herein, the term "coupled"
includes coupling via a separate object and includes direct coupling. The term "coupled" also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material. Also, the term "coupled"
may include chemical, such as via a chemical bond, mechanical, thermal, or electrical coupling. Specific non-limiting examples of the techniques by which the first barrier layer 112 may be coupled to the manifold 110 include welding (e.g., ultrasonic or RF
welding), bonding, adhesives, cements, or other coupling techniques or devices.
includes coupling via a separate object and includes direct coupling. The term "coupled" also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material. Also, the term "coupled"
may include chemical, such as via a chemical bond, mechanical, thermal, or electrical coupling. Specific non-limiting examples of the techniques by which the first barrier layer 112 may be coupled to the manifold 110 include welding (e.g., ultrasonic or RF
welding), bonding, adhesives, cements, or other coupling techniques or devices.
[0019] The manifold 110 and the first barrier layer 112 are disposed within a sealed space 118 that is formed by a drape 120 that covers both the manifold 110 and the first barrier layer 112. The sealed space 118 that is formed by the drape 120 helps to maintain a therapeutic reduced pressure at the tissue site 106 and may include various components, such as the manifold 110 and the first barrier layer 112.
[0020] The drape 120 may be any material that provides a fluid seal. The drape may, for example, be an impermeable or semi-permeable, elastomeric material.
"Elastomeric"
means having the properties of an elastomer. It generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have ultimate elongations greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation. Examples of elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. Specific examples of the drape 120 include a silicone drape, 3M Tegaderm drape, or a polyurethane drape such as one available from Avery Dennison of Pasadena, California.
"Elastomeric"
means having the properties of an elastomer. It generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have ultimate elongations greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation. Examples of elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. Specific examples of the drape 120 include a silicone drape, 3M Tegaderm drape, or a polyurethane drape such as one available from Avery Dennison of Pasadena, California.
[0021] An adhesive 121 may be used to hold the drape 120 against a patient's epidermis 138 or another layer, such as a gasket or additional drape. The adhesive 121 may take numerous forms. For example, the adhesive 121 may be a medically acceptable, pressure-sensitive adhesive that extends about a periphery 129 of the drape 120.
[0022] Reduced pressure is delivered to the sealed space 118 via a reduced-pressure interface or a connector 122. The connector 122 is at least partially disposed in an aperture 124 of the drape 120. The connector 122 may be held against the drape 120 using a second drape 126 that is held against the drape 120 using an adhesive 128. The adhesive 128 may be the same or similar to the adhesive 121 that is used to hold the drape 120 against the patient's epidermis 138. The second drape 126 can also be held against the connector 122 using an adhesive (not shown). In one illustrative embodiment, the connector 122 is a T.R.A.C. Pad or Sensa T.R.A.C. Pad available from KCI of San Antonio, Texas.
[0023] A reduced-pressure conduit 130 is used to deliver reduced pressure from the reduced-pressure source 102 to the connector 122. The reduced-pressure conduit 130 may include one or a plurality of lumens, each of which is capable of transferring reduced pressure or fluid. A medial portion 131 of the reduced-pressure conduit 130 may have one or more devices, such as a representative device 132. For example, the device 132 may be a fluid reservoir, or collection member, to hold exudates and other fluids removed from the tissue site 106. Other examples of the device 132 that may be included on the medial portion 131 of the reduced-pressure conduit 130, or otherwise fluidly coupled to the reduced-pressure conduit 130, include the following non-limiting examples: a pressure-feedback device, a volume detection system, a blood detection system, an infection detection system, a flow monitoring system, or a temperature monitoring system. Some of these devices may be formed integrally to the reduced-pressure source 102. For example, a reduced-pressure port on reduced-pressure source 102 may include a filter member that includes one or more filters, e.g., an odor filter.
Multiple devices 132 may be included.
Multiple devices 132 may be included.
[0024] The reduced-pressure source 102 may be any device for supplying a reduced pressure, such as a vacuum pump, wall suction, or other source. While the amount and nature of reduced pressure applied to the tissue site 106 will typically vary according to the application, the reduced pressure will typically be between -5 mm Hg and -500 mm Hg and more typically between -100 mm Hg and -300 mm Hg.
[0025] The first barrier layer 112 is formed from a desolidifying material.
"Desolidifying material" means a material operable to desolidify in the presence of fluid, such as a liquid. Desolidification allows fluid communication to occur where the desolifying material has desolidified. Desolidification in this context includes dissolving, degrading, breaking apart, increasing fluid permeability, or transitioning from a solid to a liquid or other state, including a gel or gas. In some embodiments, the desolidifying material is removed or dissolved in the presence of liquid and in other embodiments the desolidfying material remains in part but allows fluid communication.
"Desolidifying material" means a material operable to desolidify in the presence of fluid, such as a liquid. Desolidification allows fluid communication to occur where the desolifying material has desolidified. Desolidification in this context includes dissolving, degrading, breaking apart, increasing fluid permeability, or transitioning from a solid to a liquid or other state, including a gel or gas. In some embodiments, the desolidifying material is removed or dissolved in the presence of liquid and in other embodiments the desolidfying material remains in part but allows fluid communication.
[0026] The first barrier layer 112 may be a flexible layer capable of conforming to the contours of the tissue site 106 and desolidifying in the presence of a fluid-typically a liquid.
Non-limiting examples of materials from which the first barrier layer 112 may be formed include straight-chain polymers and a variety of water-soluble films, such as polyvinyl alcohol, polyethylene oxide, cellulose derivatives, such as the sodium salt of carboxy methyl cellulose, polyvinyl pyrrolidone, or acrylics, such as polyacrylic acid, salts of polyacrylic acid, hydroxyl and carboxyl substituted polymers, and copolymers of acrylics and polyurethanes and their salts. The first barrier layer 112 may also be formed using a bioabsorbable material that relies on biological absorption to desolidify the first barrier layer 112. Such bioabsorbable materials may desolidify in the presence of biological material present at the tissue site 106, including particular biological groups that promote healing in the wound 107.
Non-limiting examples of materials from which the first barrier layer 112 may be formed include straight-chain polymers and a variety of water-soluble films, such as polyvinyl alcohol, polyethylene oxide, cellulose derivatives, such as the sodium salt of carboxy methyl cellulose, polyvinyl pyrrolidone, or acrylics, such as polyacrylic acid, salts of polyacrylic acid, hydroxyl and carboxyl substituted polymers, and copolymers of acrylics and polyurethanes and their salts. The first barrier layer 112 may also be formed using a bioabsorbable material that relies on biological absorption to desolidify the first barrier layer 112. Such bioabsorbable materials may desolidify in the presence of biological material present at the tissue site 106, including particular biological groups that promote healing in the wound 107.
[0027] According to another illustrative, non-limiting embodiment, in operation, the dressing 104 is applied to the tissue site 106 of the patient 108 such that the first barrier layer 112 is adjacent or abutting the tissue site 106 and may be adjacent to a portion of the patient's intact epidermis 138 as shown in FIGURE IA. When the dressing 104 is applied to the tissue site 106 of the patient 108, the first barrier layer 112 may be brought into the presence of or into contact with a fluid, including a liquid. The source of this fluid is described in further detail below. The fluid desolidifies a first portion 133 of the first barrier layer 112 to form a treatment aperture 134 in the first barrier layer 112 as shown in FIGURES 1B
and 1C. The first barrier layer 112 may desolidify, at least partially, by dissolving when exposed to the fluid. The treatment aperture 134 exposes the manifold 110 to the tissue site 106 such that fluid communication is provided between the manifold 110 and the tissue site 106. In this way, reduced pressure from the reduced-pressure source 102 may be applied to the tissue site 106 through the treatment aperture 134.
and 1C. The first barrier layer 112 may desolidify, at least partially, by dissolving when exposed to the fluid. The treatment aperture 134 exposes the manifold 110 to the tissue site 106 such that fluid communication is provided between the manifold 110 and the tissue site 106. In this way, reduced pressure from the reduced-pressure source 102 may be applied to the tissue site 106 through the treatment aperture 134.
[0028] A second portion 136, or intact portion, of the first barrier layer 112 remains intact and does not desolidify when the reduced pressure is applied to the tissue site 106. The second portion 136 separates the manifold 110 from the epidermis 138 of the patient 108 and can prevent or reduce irritation of the patient's epidermis 13 8 caused by the manifold 110.
The first barrier layer 112 can have a smooth inward-facing surface 135 that facilitates the inward migration of healthy skin toward the wound 107 in the direction of arrow 140. Thus, the first barrier layer 112 encourages epithelialization of the wound 107.
Also, the first barrier layer 112 may have a moisture-vapor transmission rate (MVTR) that helps to prevent maceration of the portion of the patient's epidermis 138 that touches the second portion 136 of the first barrier layer 112. Using the illustrative embodiments, the dressing 104, and in particular the manifold 110 and the first barrier layer 112, need not be cut to fit the wound 107 because these components may overlay tissue surrounding the wound 107, such as the patient's epidermis 138, without unwanted maceration or irritation.
The first barrier layer 112 can have a smooth inward-facing surface 135 that facilitates the inward migration of healthy skin toward the wound 107 in the direction of arrow 140. Thus, the first barrier layer 112 encourages epithelialization of the wound 107.
Also, the first barrier layer 112 may have a moisture-vapor transmission rate (MVTR) that helps to prevent maceration of the portion of the patient's epidermis 138 that touches the second portion 136 of the first barrier layer 112. Using the illustrative embodiments, the dressing 104, and in particular the manifold 110 and the first barrier layer 112, need not be cut to fit the wound 107 because these components may overlay tissue surrounding the wound 107, such as the patient's epidermis 138, without unwanted maceration or irritation.
[0029] The fluid that causes the desolidification of at least a portion of the first barrier layer 112 may come from any of a variety of sources. For example, when reduced pressure is applied to the wound 107, exudate from the wound 107 may be drawn toward the first barrier layer 112 as indicated by the arrows 142. The exudate may then desolidify the first portion 133 of the first barrier layer 112 with which the exudate comes into contact to create the treatment aperture 134. In another, illustrative, non-limiting embodiment, a gel (not shown) may be applied to the tissue site 106 or the wound 107 prior to applying the dressing 104 to the tissue site 106. The gel, which may be a water-based gel, may then act to desolidify the first portion 133 of the first barrier layer 112 with which the gel comes into contact. In yet another illustrative, non-limiting example, fluid may be provided to the dressing 104, and in particular the first barrier layer 112, by a fluid source (not shown) that supplies fluid through the reduced-pressure conduit 130. In one embodiment, the device 132 may act as the fluid source.
[0030] The dressing 104 may be used on both dry and wet tissue sites. In the example in which the first barrier layer 112 is used on a relatively dry tissue site, the first barrier layer 112 may be formed from a material that desolidifies in the presence of a lower amount of fluid. Alternatively, a gel, including a water-based gel, or colloid may be applied to the relatively dry tissue site before applying the dressing 104, and this pre-applied gel will cause the first barrier layer 112 to desolidify. In the contrasting case in which the tissue site 106 is relatively moist, the first barrier layer 112 may be formed from a material that desolidifies in response to larger amounts of fluid.
[0031] In another illustrative, non-limiting embodiment, the first barrier layer 112, when brought into the presence of a fluid, may first turn into a gel before desolidifying into a liquid. The gel formed during the transition period between the solid and liquidified first barrier layer 112 may contain healing agents that are released into the wound 107. Examples of the healing agents that may be released from this gel include ionic groups, antimicrobials, anti-inflammatory factors, and growth factors. Other healing factors that are beneficial to the condition of the wound 107 or epidermis 138 and that encourage epithelialization may also be included in the gel. When the first barrier layer 112 desolidifies into a liquid, the liquid may be drawn through the manifold 110 and out of the dressing 104 using the reduced pressure that is supplied by the reduced-pressure source 102.
[0032] In other illustrative, non-limiting embodiments, additional layers may be added to the sealed space 118. For example, an absorbent layer, another manifold layer, another barrier layer, or other layers or components that facilitate reduced-pressure therapy may be included in the dressing 104 and disposed in the sealed space 118.
[0033] Referring now primarily to FIGURE 2, another illustrative, non-limiting embodiment, the manifold 110 includes two surfaces 144 and 146 covered by the first barrier layer 112 and a second barrier layer 148, respectively. The first barrier layer 112 and the second barrier layer 148 may be formed from the same or different materials.
In the example in which the first and second barrier layers 112, 148 are formed from a same or similar material, a caregiver may pay little or no regard to whether the first barrier layer 112 or the second barrier layer 148 is deployed adjacent to the tissue site, e.g., the tissue site 106 in FIGURE 1. In the example in which the first and second barrier layers 112, 148 are different, however, a caregiver may choose between placing either the first or second barrier layers 112, 148 against the tissue site 106 based on the properties of each barrier layer 112, 148. The first and second barrier layers 112, 148 may each have different properties that are adapted for treating different types of wounds or conditions. For example, the first barrier layer 112 may be formed from a material that requires less fluid to desolidify than the second barrier layer 148. In this example, the first barrier layer 112 may be used for relatively drier wounds than the wounds for which the second barrier layer 148 is used.
In the example in which the first and second barrier layers 112, 148 are formed from a same or similar material, a caregiver may pay little or no regard to whether the first barrier layer 112 or the second barrier layer 148 is deployed adjacent to the tissue site, e.g., the tissue site 106 in FIGURE 1. In the example in which the first and second barrier layers 112, 148 are different, however, a caregiver may choose between placing either the first or second barrier layers 112, 148 against the tissue site 106 based on the properties of each barrier layer 112, 148. The first and second barrier layers 112, 148 may each have different properties that are adapted for treating different types of wounds or conditions. For example, the first barrier layer 112 may be formed from a material that requires less fluid to desolidify than the second barrier layer 148. In this example, the first barrier layer 112 may be used for relatively drier wounds than the wounds for which the second barrier layer 148 is used.
[0034] The first and second barrier layers 112, 148 may also differ in other respects.
For example, the first and second barrier layers 112, 148 may each respectively contain different healing agents that are adapted for different tissues or wound types. The first and second barrier layers 112, 148 may also each have a different moisture vapor transmission rates, hardness, smoothness, thickness, or other properties. In another illustrative, non-limiting example, either or both of the first and second barrier layers 112, 148 may be partially or wholly formed from a debridement material that encourages debridement at the tissue site through autolytic mechanisms. Either or both of the first and second barrier layers 112, 148 may also be able to release debridement agents (e.g., enzymes) that break down tissue, such as eschar and necrotic tissue. In another illustrative, non-limiting embodiment, each lateral side 150, 152 of the manifold 110 may also be covered by a barrier layer.
For example, the first and second barrier layers 112, 148 may each respectively contain different healing agents that are adapted for different tissues or wound types. The first and second barrier layers 112, 148 may also each have a different moisture vapor transmission rates, hardness, smoothness, thickness, or other properties. In another illustrative, non-limiting example, either or both of the first and second barrier layers 112, 148 may be partially or wholly formed from a debridement material that encourages debridement at the tissue site through autolytic mechanisms. Either or both of the first and second barrier layers 112, 148 may also be able to release debridement agents (e.g., enzymes) that break down tissue, such as eschar and necrotic tissue. In another illustrative, non-limiting embodiment, each lateral side 150, 152 of the manifold 110 may also be covered by a barrier layer.
[0035] Referring now primarily to FIGURE 3, a first barrier layer 154 having perforations 156 covers a first surface 144 of a manifold 110. The perforations 156 in the first barrier layer 154 provide immediate fluid communication between the manifold 110 and a tissue site when the dressing associated therewith is applied to the tissue site. Thus, reduced pressure may be applied to the tissue site, via the perforations 156, before the first barrier layer 154 desolidifies. The perforations 156 may be uniform or non-uniform in size and may take any shape. The perforations 156 may be engulfed, or simply disappear, when the first barrier layer 154 desolidifies.
[0036] In another illustrative, non-limiting embodiment, the second barrier layer 148 may also include a plurality of perforations (not shown). In this embodiment, the percentage of the total surface area of each of the first and second barrier layers 154, 148 that is occupied by the perforations in each of these barrier layers 154, 148 may differ. For example, the first barrier layer 154 may have a higher density of perforations 156 than the second barrier layer 148. The perforations 156 in the first barrier layer 154 may also be larger or smaller than the perforations in the second barrier layer 148.
[0037] The perforations in each of the first and second barrier layers 154, 148 may also provide different fluid flow rates for each of these barrier layers before or during the time at which they desolidify. In this example, the perforations 156 in the first barrier layer 154 provide a flow rate X across the first barrier layer 154 for a given fluid and reduced pressure, while the perforations in the second barrier layer 148 provide a flow rate Y
across the second barrier layer 148 for the same fluid and reduced pressure. The flow rate Y may be the same as or greater than X. By differing the flow rates between the first and second barrier layers 154, 148, each of these barrier layers may be used for particular types of wounds.
In the example in which the second barrier layer 148 has a flow rate Y greater than the flow rate X in the first barrier layer 154, the second barrier layer 148 may be suited for placement adjacent to wounds that are drier wounds. These aforementioned embodiments that include differing barrier layers on different sides of the manifold 110 allow a caregiver to provide two treatment scenarios with a single dressing.
across the second barrier layer 148 for the same fluid and reduced pressure. The flow rate Y may be the same as or greater than X. By differing the flow rates between the first and second barrier layers 154, 148, each of these barrier layers may be used for particular types of wounds.
In the example in which the second barrier layer 148 has a flow rate Y greater than the flow rate X in the first barrier layer 154, the second barrier layer 148 may be suited for placement adjacent to wounds that are drier wounds. These aforementioned embodiments that include differing barrier layers on different sides of the manifold 110 allow a caregiver to provide two treatment scenarios with a single dressing.
[0038] Although the present invention and its advantages have been disclosed in the context of certain illustrative, non-limiting embodiments, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope of the invention as defined by the appended claims. It will be appreciated that any feature that is described in connection to any one embodiment may also be applicable to any other embodiment.
Claims (38)
- Claim 1. A system for providing reduced-pressure therapy to a tissue site of a patient, the system comprising:
a reduced-pressure source for supplying reduced pressure;
a manifold having a first, inward-facing surface and a second surface, the manifold operable to transfer the reduced pressure;
a first barrier layer covering at least a portion of the first, inward-facing surface of the manifold, the first barrier layer for placement adjacent to the tissue site, the first barrier layer formed from a desolidifying material; and a drape for covering the second surface of the manifold and a portion of the patient's epidermis to provide a substantially sealed space containing the manifold and the first barrier layer. - Claim 2. The system of claim 1, wherein the drape includes an aperture, and wherein the system further comprises:
a reduced-pressure conduit for transferring reduced pressure; and a reduced-pressure connector for disposing in the aperture and providing fluid communication between the reduced-pressure conduit and the manifold. - Claim 3. The system of claim 1, further comprising:
a second barrier layer covering the second surface of the manifold, the second barrier layer operable to desolidify in the presence of fluid to expose the manifold. - Claim 4. The system of claim 1, further comprising:
a second barrier layer covering the second surface of the manifold, the second barrier layer operable to desolidify in the presence of fluid to expose the manifold to the tissue site, wherein the second barrier layer desolidifies at a faster rate than the first barrier layer when in the presence of the fluid. - Claim 5. The system of claim 1, wherein the first barrier layer covers each surface of the manifold.
- Claim 6. The system of claim 1, wherein the first barrier layer is formed with a plurality of perforations for providing fluid communication across the first barrier layer.
- Claim 7. The system of claim 1, wherein the first barrier layer comprises a first plurality of perforations for providing fluid communication across the first barrier layer, and further comprising:
a second barrier layer on the second surface of the manifold, the second barrier layer comprising a second plurality of perforations for providing fluid communication across the second barrier layer. - Claim 8. The system of claim 1, wherein the first barrier layer comprises a first plurality of perforations for providing fluid communication across the first barrier layer, and further comprising:
a second barrier layer on the second surface of the manifold, the second barrier layer comprising a second plurality of perforations for providing fluid communication across the second barrier layer, the second barrier layer having a higher density of perforations than the first barrier layer. - Claim 9. The system of claim 1, wherein the first barrier layer comprises a first plurality of perforations for providing a flow rate (X) across the first barrier layer, and further comprising:
a second barrier layer on the second surface of the manifold, the second barrier layer comprising a second plurality of perforations for providing a flow rate (Y) across the second barrier layer, wherein Y is greater than X. - Claim 10. The system of claim 1, wherein the first barrier layer is operable to desolidify into a liquid when contacting a fluid.
- Claim 11. The system of claim 1, wherein the first barrier layer includes a healing agent, and wherein the healing agent is released at the tissue site as the first barrier layer desolidifies.
- Claim 12. The system of claim 1, wherein the first barrier layer is operable to desolidify to form a treatment aperture, the treatment aperture providing fluid communication between the manifold and the tissue site.
- Claim 13. The system of claim 1, wherein the desolidifying material dissolves in the presence of a liquid.
- Claim 14. The system of claim 1, wherein the desolidifying material is water soluble.
- Claim 15. The system of claim 1, wherein the desolidifying material breaks apart in the presence of a liquid.
- Claim 16. The system of claim 1, wherein the desolidifying material becomes substantially fluid permeable in the presence of a liquid.
- Claim 17. An apparatus for providing reduced-pressure therapy to a tissue site of a patient, the apparatus comprising:
a manifold having a first, inward-facing surface and a second surface, the manifold operable to transfer reduced pressure; and a first barrier layer covering at least a portion of the first, inward-facing surface of the manifold, the first barrier layer formed from a desolidifying material. - Claim 18. The apparatus of claim 17, further comprising:
a second barrier layer covering the second surface of the manifold, the second barrier layer operable to desolidify in the presence of a fluid to expose the manifold to the tissue site. - Claim 19. The apparatus of claim 17, further comprising:
a second barrier layer covering the second surface of the manifold, the second barrier layer operable to desolidify in the presence of a fluid to expose the manifold to the tissue site, and wherein the second barrier layer desolidifies at a faster rate than the first barrier layer when in the presence of the fluid. - Claim 20. The apparatus of claim 17, wherein the first barrier layer covers each surface of the manifold.
- Claim 21. The apparatus of claim 17, wherein the first barrier layer comprises a plurality of perforations providing fluid communication across the first barrier layer.
- Claim 22. The apparatus of claim 17, wherein the first barrier layer comprises a first plurality of perforations for providing fluid communication across the first barrier layer, and further comprising:
a second barrier layer on the second surface of the manifold, the second barrier layer comprising a second plurality of perforations for providing fluid communication across the second barrier layer. - Claim 23. The apparatus of claim 17, wherein the first barrier layer comprises a first plurality of perforations for providing fluid communication across the first barrier layer, and further comprising:
a second barrier layer on the second surface of the manifold, the second barrier layer comprising a second plurality of perforations for providing fluid communication across the second barrier layer, and wherein the second barrier layer has a higher density of perforations than the first barrier layer. - Claim 24. The apparatus of claim 17, wherein the first barrier layer comprises a first plurality of perforations for providing a flow rate (X) across the first barrier layer, and further comprising:
a second barrier layer on the second surface of the manifold, the second barrier layer comprising a second plurality of perforations for providing a flow rate (Y) across the second barrier layer, wherein Y is greater than X. - Claim 25. The apparatus of claim 17, wherein the first barrier layer is operable to desolidify into a liquid when contacting the fluid.
- Claim 26. The apparatus of claim 17, wherein the first barrier layer includes a healing agent, and wherein the healing agent is released as the first barrier layer desolidifies.
- Claim 27. The apparatus of claim 17, wherein the first barrier layer is operable to desolidify to form a treatment aperture, the treatment aperture for providing fluid communication between the manifold and the tissue site.
- Claim 28. A method for providing reduced-pressure therapy to a tissue site of a patient, the method comprising:
applying a dressing to the tissue site, the dressing comprising:
a manifold having a first, inward-facing surface and a second surface, the manifold operable to transfer reduced pressure, and a first barrier layer covering at least a portion of the first, inward-facing surface of the manifold, the first barrier layer formed from a desolidifying material;
allowing fluid at the tissue site to desolidify at least a portion of the first barrier layer to create a treatment aperture; and applying a reduced pressure to the tissue site via the treatment aperture. - Claim 29. The method of claim 28, wherein applying the dressing to the tissue site includes covering a wound and epidermis surrounding the wound with the first barrier layer.
- Claim 30. The method of claim 28, further comprising:
applying a gel to the tissue site prior to applying the dressing to the tissue site. - Claim 31. The method of claim 28, wherein applying the reduced pressure to the tissue site includes drawing a desolidified portion of the first barrier layer material out of the dressing via the manifold.
- Claim 32. The method of claim 31, wherein the tissue site includes a wound and the fluid at the tissue site is exudate from the wound.
- Claim 33. The method of claim 28, wherein the first barrier layer includes a healing agent and further comprising releasing the healing agent from the first barrier layer.
- Claim 34. The method of claim 28, further comprising:
applying a fluid to the dressing from a fluid source to facilitate the desolidification of the first barrier layer. - Claim 35. The method of claim 28, wherein applying the dressing to the tissue site includes covering the manifold and the first barrier layer with a drape to provide a substantially sealed space containing the manifold and the first barrier layer.
- Claim 36. The method of claim 28, wherein the first barrier layer is disposed between the manifold and the tissue site when the dressing is deployed in the tissue site.
- Claim 37. A method of manufacturing an apparatus for providing reduced-pressure therapy to a tissue site of a patient, the method comprising:
providing a manifold having a first, inward-facing surface and a second surface;
providing a first barrier layer formed from a desolidifying material; and coupling the first barrier layer to the first, inward-facing surface of the manifold. - Claim 38. The method of claim 37, further comprising:
providing a second barrier layer operable to desolidify in the presence of fluid; and coupling the second barrier layer to the second surface of the manifold.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22560409P | 2009-07-15 | 2009-07-15 | |
US61/225,604 | 2009-07-15 | ||
US12/823,958 US8469936B2 (en) | 2009-07-15 | 2010-06-25 | Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers |
US12/823,958 | 2010-06-25 | ||
PCT/US2010/040218 WO2011008497A2 (en) | 2009-07-15 | 2010-06-28 | Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2767982A1 true CA2767982A1 (en) | 2011-01-20 |
CA2767982C CA2767982C (en) | 2018-07-17 |
Family
ID=43131902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2767982A Expired - Fee Related CA2767982C (en) | 2009-07-15 | 2010-06-28 | Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers |
Country Status (10)
Country | Link |
---|---|
US (2) | US8469936B2 (en) |
EP (3) | EP2801380B1 (en) |
JP (3) | JP5561802B2 (en) |
CN (2) | CN104474596B (en) |
AU (2) | AU2010273826B2 (en) |
BR (1) | BR112012000869A2 (en) |
CA (1) | CA2767982C (en) |
SG (1) | SG177489A1 (en) |
TW (1) | TW201113055A (en) |
WO (1) | WO2011008497A2 (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2455962A (en) | 2007-12-24 | 2009-07-01 | Ethicon Inc | Reinforced adhesive backing sheet, for plaster |
KR101608548B1 (en) | 2008-03-05 | 2016-04-01 | 케이씨아이 라이센싱 인코포레이티드 | Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site |
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
US20110106058A1 (en) * | 2009-10-29 | 2011-05-05 | Pal Svedman | Adhesive Flange Attachment Reinforcer For Suction Port |
US8814842B2 (en) | 2010-03-16 | 2014-08-26 | Kci Licensing, Inc. | Delivery-and-fluid-storage bridges for use with reduced-pressure systems |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
US9526816B2 (en) | 2010-12-08 | 2016-12-27 | Convatec Technologies Inc. | Wound exudate monitor accessory |
JP5965409B2 (en) | 2010-12-08 | 2016-08-03 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | Integrated system for assessing wound exudate |
GB2488749A (en) | 2011-01-31 | 2012-09-12 | Systagenix Wound Man Ip Co Bv | Laminated silicone coated wound dressing |
US9421132B2 (en) | 2011-02-04 | 2016-08-23 | University Of Massachusetts | Negative pressure wound closure device |
CN106974683B (en) * | 2011-02-04 | 2020-02-21 | 马萨诸塞州大学 | Negative pressure wound closure device |
GB201106491D0 (en) | 2011-04-15 | 2011-06-01 | Systagenix Wound Man Ip Co Bv | Patterened silicone coating |
ES2571402T3 (en) * | 2011-04-18 | 2016-05-25 | Rigshospitalet Copenhagen Univ Hospital | Enhanced wound care product |
AU2012333210B2 (en) | 2011-06-24 | 2017-01-19 | Solventum Intellectual Properties Company | Reduced-pressure dressings employing tissue-fixation elements |
DE102011108726A1 (en) * | 2011-07-26 | 2013-01-31 | Paul Hartmann Ag | Connection device for use in the vacuum treatment of wounds |
GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
GB201120693D0 (en) | 2011-12-01 | 2012-01-11 | Convatec Technologies Inc | Wound dressing for use in vacuum therapy |
US10940047B2 (en) | 2011-12-16 | 2021-03-09 | Kci Licensing, Inc. | Sealing systems and methods employing a hybrid switchable drape |
US9861532B2 (en) | 2011-12-16 | 2018-01-09 | Kci Licensing, Inc. | Releasable medical drapes |
CA2858110C (en) * | 2012-02-02 | 2020-09-22 | Kci Licensing, Inc. | Foam structure wound inserts for directional granulation |
CA2874581C (en) | 2012-05-24 | 2022-06-07 | Smith & Nephew Inc. | Devices and methods for treating and closing wounds with negative pressure |
US9962295B2 (en) | 2012-07-16 | 2018-05-08 | Smith & Nephew, Inc. | Negative pressure wound closure device |
US9844614B2 (en) * | 2012-10-01 | 2017-12-19 | Mölnlycke Health Care Ab | Wound therapy device |
SG11201503860RA (en) | 2012-11-16 | 2015-06-29 | Kci Licensing Inc | Medical drape with pattern adhesive layers and method of manufacturing same |
GB201222770D0 (en) | 2012-12-18 | 2013-01-30 | Systagenix Wound Man Ip Co Bv | Wound dressing with adhesive margin |
EP2935688A2 (en) | 2012-12-20 | 2015-10-28 | ConvaTec Technologies Inc. | Processing of chemically modified cellulosic fibres |
US10124098B2 (en) | 2013-03-13 | 2018-11-13 | Smith & Nephew, Inc. | Negative pressure wound closure device and systems and methods of use in treating wounds with negative pressure |
WO2014143488A1 (en) | 2013-03-14 | 2014-09-18 | Kci Licensing, Inc. | Absorbent dressing with hybrid drape |
WO2015030963A1 (en) | 2013-08-26 | 2015-03-05 | Kci Licensing, Inc. | Dressing interface with moisture controlling feature and sealing function |
EP3062753B1 (en) | 2013-10-28 | 2018-11-21 | KCI Licensing, Inc. | Hybrid sealing tape |
EP3513773A1 (en) | 2013-10-30 | 2019-07-24 | KCI Licensing, Inc. | Condensate absorbing and dissipating system |
EP3744361A1 (en) | 2013-10-30 | 2020-12-02 | KCI Licensing, Inc. | Absorbent conduit and system |
CN110652396B (en) | 2013-10-30 | 2021-11-23 | 3M创新知识产权公司 | Dressing with perforations of different sizes |
US9956120B2 (en) | 2013-10-30 | 2018-05-01 | Kci Licensing, Inc. | Dressing with sealing and retention interface |
CA2940730C (en) | 2014-02-28 | 2022-07-26 | Kci Licensing, Inc. | Hybrid drape having a gel-coated perforated mesh |
US11026844B2 (en) | 2014-03-03 | 2021-06-08 | Kci Licensing, Inc. | Low profile flexible pressure transmission conduit |
US10406266B2 (en) | 2014-05-02 | 2019-09-10 | Kci Licensing, Inc. | Fluid storage devices, systems, and methods |
JP6670827B2 (en) | 2014-05-16 | 2020-03-25 | スリーエム イノベイティブ プロパティズ カンパニー | Article including porous elastomeric material with integrated elastomeric material and method of making same |
EP3281616B1 (en) | 2014-06-05 | 2020-01-01 | KCI Licensing, Inc. | Dressing with fluid acquisition and distribution characteristics |
US10398604B2 (en) | 2014-12-17 | 2019-09-03 | Kci Licensing, Inc. | Dressing with offloading capability |
KR101633497B1 (en) * | 2015-02-10 | 2016-06-24 | (주)시지바이오 | A method and apparatus for measuring volum of wound |
WO2016176513A1 (en) | 2015-04-29 | 2016-11-03 | Smith & Nephew Inc. | Negative pressure wound closure device |
US11246975B2 (en) | 2015-05-08 | 2022-02-15 | Kci Licensing, Inc. | Low acuity dressing with integral pump |
EP3344205B1 (en) | 2015-09-01 | 2020-09-30 | KCI Licensing, Inc. | Dressing with increased apposition force |
EP3349807B1 (en) | 2015-09-17 | 2021-02-24 | 3M Innovative Properties Company | Hybrid silicone and acrylic adhesive cover for use with wound treatment |
KR101744708B1 (en) | 2015-10-16 | 2017-06-09 | (주)시지바이오 | Connector for reduced pressure treatment and a reduced pressure treatment apparatus using the same |
US11471586B2 (en) | 2015-12-15 | 2022-10-18 | University Of Massachusetts | Negative pressure wound closure devices and methods |
CA3019445A1 (en) | 2016-03-30 | 2017-12-14 | Synovo Gmbh | Detecting microbial infection in wounds |
UY37178A (en) | 2016-03-30 | 2017-10-31 | Convatec Technologies Inc | DETECTION OF MICROBIAL INFECTION IN WOUNDS |
KR20190028467A (en) | 2016-07-08 | 2019-03-18 | 컨바텍 테크놀러지스 인크 | Body fluid collecting device |
US11596554B2 (en) | 2016-07-08 | 2023-03-07 | Convatec Technologies Inc. | Flexible negative pressure system |
CA3030153C (en) | 2016-07-08 | 2023-10-24 | Convatec Technologies Inc. | Fluid flow sensing |
WO2018170132A1 (en) | 2017-03-14 | 2018-09-20 | University Of Connecticut | Biodegradable pressure sensor |
EP3960138B8 (en) * | 2017-05-16 | 2024-04-03 | Solventum Intellectual Properties Company | An absorbent negative-pressure dressing system for use with post-surgical breast wounds |
AU2018280130A1 (en) | 2017-06-07 | 2019-12-19 | 3M Innovative Properties Company | Composite dressings for improved granulation reduced maceration with negative-pressure treatment |
CN110691573A (en) | 2017-06-07 | 2020-01-14 | 凯希特许有限公司 | Peel-and-place dressing for negative pressure therapy |
WO2018226705A1 (en) | 2017-06-07 | 2018-12-13 | Kci Licensing, Inc. | Composite dressings for improved granulation and reduced maceration with negative-pressure treatment |
EP3634329B1 (en) | 2017-06-07 | 2020-12-23 | 3M Innovative Properties Company | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
EP3634519B1 (en) | 2017-06-07 | 2023-05-31 | 3M Innovative Properties Company | Systems, apparatuses, and methods for negative-pressure treatment with reduced tissue in-growth |
CN110831553A (en) | 2017-06-07 | 2020-02-21 | 凯希特许有限公司 | Composite dressing for improving granulation growth and reducing maceration by negative pressure therapy |
CN110709038B (en) | 2017-06-07 | 2022-09-02 | 3M创新知识产权公司 | Composite dressing for improving granulation growth and reducing maceration by negative pressure therapy |
WO2018226691A1 (en) | 2017-06-07 | 2018-12-13 | Kci Licensing, Inc. | Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy |
EP3634334B1 (en) | 2017-06-07 | 2023-05-24 | 3M Innovative Properties Company | Multi-layer wound filler for extended wear time |
AU2018285235B2 (en) | 2017-06-14 | 2023-11-02 | T.J.Smith & Nephew, Limited | Negative pressure wound therapy apparatus |
WO2019060667A1 (en) | 2017-09-22 | 2019-03-28 | Kci Licensing, Inc. | Wound dressings and systems with high-flow therapeutic gas sources for topical wound therapy and related methods |
US11141523B2 (en) | 2017-10-26 | 2021-10-12 | Kci Licensing, Inc. | Wound dressings and systems for effluent management of topical wound therapy and related methods |
US20210001021A1 (en) * | 2018-01-10 | 2021-01-07 | Kci Licensing, Inc. | Wound dressings and systems with therapeutic gas and negative pressure sources for incision management and related methods |
US11576818B2 (en) | 2018-01-10 | 2023-02-14 | Kci Licensing, Inc. | Negative pressure wound therapy dressings with local oxygen generation for topical wound therapy and related methods |
EP3876885B1 (en) * | 2018-11-08 | 2023-11-29 | 3M Innovative Properties Company | Wound dressing with semi-rigid support to increase disruption using perforated dressing and negative pressure wound therapy |
US11826495B2 (en) | 2019-03-01 | 2023-11-28 | University Of Connecticut | Biodegradable piezoelectric ultrasonic transducer system |
WO2021038444A1 (en) * | 2019-08-28 | 2021-03-04 | Kci Licensing, Inc. | Pneumatic pressure massage device |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
WO2021183626A1 (en) | 2020-03-10 | 2021-09-16 | University Of Connecticut | Therapeutic bandage |
Family Cites Families (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1355846A (en) * | 1920-02-06 | 1920-10-19 | David A Rannells | Medical appliance |
US2547758A (en) * | 1949-01-05 | 1951-04-03 | Wilmer B Keeling | Instrument for treating the male urethra |
US2632443A (en) * | 1949-04-18 | 1953-03-24 | Eleanor P Lesher | Surgical dressing |
GB692578A (en) | 1949-09-13 | 1953-06-10 | Minnesota Mining & Mfg | Improvements in or relating to drape sheets for surgical use |
US2682873A (en) * | 1952-07-30 | 1954-07-06 | Johnson & Johnson | General purpose protective dressing |
NL189176B (en) * | 1956-07-13 | 1900-01-01 | Hisamitsu Pharmaceutical Co | PLASTER BASED ON A SYNTHETIC RUBBER. |
US2969057A (en) * | 1957-11-04 | 1961-01-24 | Brady Co W H | Nematodic swab |
US3066672A (en) | 1960-09-27 | 1962-12-04 | Jr William H Crosby | Method and apparatus for serial sampling of intestinal juice |
US3367332A (en) * | 1965-08-27 | 1968-02-06 | Gen Electric | Product and process for establishing a sterile area of skin |
US3520300A (en) * | 1967-03-15 | 1970-07-14 | Amp Inc | Surgical sponge and suction device |
US3568675A (en) * | 1968-08-30 | 1971-03-09 | Clyde B Harvey | Fistula and penetrating wound dressing |
US3682180A (en) * | 1970-06-08 | 1972-08-08 | Coilform Co Inc | Drain clip for surgical drain |
BE789293Q (en) * | 1970-12-07 | 1973-01-15 | Parke Davis & Co | MEDICO-SURGICAL DRESSING FOR BURNS AND SIMILAR LESIONS |
US3826254A (en) * | 1973-02-26 | 1974-07-30 | Verco Ind | Needle or catheter retaining appliance |
DE2527706A1 (en) * | 1975-06-21 | 1976-12-30 | Hanfried Dr Med Weigand | DEVICE FOR THE INTRODUCTION OF CONTRAST AGENTS INTO AN ARTIFICIAL INTESTINAL OUTLET |
DE2640413C3 (en) | 1976-09-08 | 1980-03-27 | Richard Wolf Gmbh, 7134 Knittlingen | Catheter monitor |
NL7710909A (en) * | 1976-10-08 | 1978-04-11 | Smith & Nephew | COMPOSITE STRAPS. |
GB1562244A (en) * | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
US4080970A (en) * | 1976-11-17 | 1978-03-28 | Miller Thomas J | Post-operative combination dressing and internal drain tube with external shield and tube connector |
US4139004A (en) * | 1977-02-17 | 1979-02-13 | Gonzalez Jr Harry | Bandage apparatus for treating burns |
US4184510A (en) * | 1977-03-15 | 1980-01-22 | Fibra-Sonics, Inc. | Valued device for controlling vacuum in surgery |
US4135748A (en) * | 1977-06-21 | 1979-01-23 | Roberts Charles K | Portable door lock |
US4165748A (en) | 1977-11-07 | 1979-08-28 | Johnson Melissa C | Catheter tube holder |
US4245637A (en) * | 1978-07-10 | 1981-01-20 | Nichols Robert L | Shutoff valve sleeve |
SE414994B (en) * | 1978-11-28 | 1980-09-01 | Landstingens Inkopscentral | VENKATETERFORBAND |
WO1980001139A1 (en) * | 1978-12-06 | 1980-06-12 | Svedman Paul | Device for treating tissues,for example skin |
US4266545A (en) | 1979-04-06 | 1981-05-12 | Moss James P | Portable suction device for collecting fluids from a closed wound |
US4284079A (en) * | 1979-06-28 | 1981-08-18 | Adair Edwin Lloyd | Method for applying a male incontinence device |
US4261363A (en) * | 1979-11-09 | 1981-04-14 | C. R. Bard, Inc. | Retention clips for body fluid drains |
US4569348A (en) * | 1980-02-22 | 1986-02-11 | Velcro Usa Inc. | Catheter tube holder strap |
ATE14835T1 (en) | 1980-03-11 | 1985-08-15 | Schmid Eduard | SKIN GRAFT PRESSURE BANDAGE. |
US4297995A (en) | 1980-06-03 | 1981-11-03 | Key Pharmaceuticals, Inc. | Bandage containing attachment post |
US4333468A (en) * | 1980-08-18 | 1982-06-08 | Geist Robert W | Mesentery tube holder apparatus |
US4465485A (en) * | 1981-03-06 | 1984-08-14 | Becton, Dickinson And Company | Suction canister with unitary shut-off valve and filter features |
US4392853A (en) * | 1981-03-16 | 1983-07-12 | Rudolph Muto | Sterile assembly for protecting and fastening an indwelling device |
US4373519A (en) * | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
US4392858A (en) * | 1981-07-16 | 1983-07-12 | Sherwood Medical Company | Wound drainage device |
US4419097A (en) | 1981-07-31 | 1983-12-06 | Rexar Industries, Inc. | Attachment for catheter tube |
AU550575B2 (en) | 1981-08-07 | 1986-03-27 | Richard Christian Wright | Wound drainage device |
SE429197B (en) * | 1981-10-14 | 1983-08-22 | Frese Nielsen | SAR TREATMENT DEVICE |
DE3146266A1 (en) * | 1981-11-21 | 1983-06-01 | B. Braun Melsungen Ag, 3508 Melsungen | COMBINED DEVICE FOR A MEDICAL SUCTION DRAINAGE |
US4551139A (en) | 1982-02-08 | 1985-11-05 | Marion Laboratories, Inc. | Method and apparatus for burn wound treatment |
US4475909A (en) * | 1982-05-06 | 1984-10-09 | Eisenberg Melvin I | Male urinary device and method for applying the device |
EP0100148B1 (en) | 1982-07-06 | 1986-01-08 | Dow Corning Limited | Medical-surgical dressing and a process for the production thereof |
NZ206837A (en) | 1983-01-27 | 1986-08-08 | Johnson & Johnson Prod Inc | Thin film adhesive dressing:backing material in three sections |
US4548202A (en) * | 1983-06-20 | 1985-10-22 | Ethicon, Inc. | Mesh tissue fasteners |
US4540412A (en) * | 1983-07-14 | 1985-09-10 | The Kendall Company | Device for moist heat therapy |
US4543100A (en) * | 1983-11-01 | 1985-09-24 | Brodsky Stuart A | Catheter and drain tube retainer |
US4525374A (en) * | 1984-02-27 | 1985-06-25 | Manresa, Inc. | Treating hydrophobic filters to render them hydrophilic |
GB2157958A (en) | 1984-05-03 | 1985-11-06 | Ernest Edward Austen Bedding | Ball game net support |
US4897081A (en) * | 1984-05-25 | 1990-01-30 | Thermedics Inc. | Percutaneous access device |
US5215522A (en) * | 1984-07-23 | 1993-06-01 | Ballard Medical Products | Single use medical aspirating device and method |
GB8419745D0 (en) * | 1984-08-02 | 1984-09-05 | Smith & Nephew Ass | Wound dressing |
US4872450A (en) * | 1984-08-17 | 1989-10-10 | Austad Eric D | Wound dressing and method of forming same |
JPH0762736B2 (en) * | 1984-09-25 | 1995-07-05 | オリンパス光学工業株式会社 | Image transmission optics |
US4826494A (en) * | 1984-11-09 | 1989-05-02 | Stryker Corporation | Vacuum wound drainage system |
US4655754A (en) * | 1984-11-09 | 1987-04-07 | Stryker Corporation | Vacuum wound drainage system and lipids baffle therefor |
US4605399A (en) * | 1984-12-04 | 1986-08-12 | Complex, Inc. | Transdermal infusion device |
US5037397A (en) * | 1985-05-03 | 1991-08-06 | Medical Distributors, Inc. | Universal clamp |
US4640688A (en) * | 1985-08-23 | 1987-02-03 | Mentor Corporation | Urine collection catheter |
US4710165A (en) | 1985-09-16 | 1987-12-01 | Mcneil Charles B | Wearable, variable rate suction/collection device |
US4758220A (en) * | 1985-09-26 | 1988-07-19 | Alcon Laboratories, Inc. | Surgical cassette proximity sensing and latching apparatus |
US4733659A (en) * | 1986-01-17 | 1988-03-29 | Seton Company | Foam bandage |
EP0256060A1 (en) | 1986-01-31 | 1988-02-24 | OSMOND, Roger L. W. | Suction system for wound and gastro-intestinal drainage |
US4838883A (en) * | 1986-03-07 | 1989-06-13 | Nissho Corporation | Urine-collecting device |
JPS62281965A (en) * | 1986-05-29 | 1987-12-07 | テルモ株式会社 | Catheter and catheter fixing member |
GB8621884D0 (en) * | 1986-09-11 | 1986-10-15 | Bard Ltd | Catheter applicator |
GB2195255B (en) | 1986-09-30 | 1991-05-01 | Vacutec Uk Limited | Apparatus for vacuum treatment of an epidermal surface |
US4743232A (en) * | 1986-10-06 | 1988-05-10 | The Clinipad Corporation | Package assembly for plastic film bandage |
DE3634569A1 (en) | 1986-10-10 | 1988-04-21 | Sachse Hans E | CONDOM CATHETER, A URINE TUBE CATHETER FOR PREVENTING RISING INFECTIONS |
JPS63135179A (en) * | 1986-11-26 | 1988-06-07 | 立花 俊郎 | Subcataneous drug administration set |
GB8628564D0 (en) | 1986-11-28 | 1987-01-07 | Smiths Industries Plc | Anti-foaming agent suction apparatus |
GB8706116D0 (en) * | 1987-03-14 | 1987-04-15 | Smith & Nephew Ass | Adhesive dressings |
US4787888A (en) | 1987-06-01 | 1988-11-29 | University Of Connecticut | Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a) |
US4863449A (en) * | 1987-07-06 | 1989-09-05 | Hollister Incorporated | Adhesive-lined elastic condom cathether |
US5176663A (en) * | 1987-12-02 | 1993-01-05 | Pal Svedman | Dressing having pad with compressibility limiting elements |
US4906240A (en) * | 1988-02-01 | 1990-03-06 | Matrix Medica, Inc. | Adhesive-faced porous absorbent sheet and method of making same |
US4985019A (en) * | 1988-03-11 | 1991-01-15 | Michelson Gary K | X-ray marker |
GB8812803D0 (en) | 1988-05-28 | 1988-06-29 | Smiths Industries Plc | Medico-surgical containers |
US4919654A (en) * | 1988-08-03 | 1990-04-24 | Kalt Medical Corporation | IV clamp with membrane |
US5000741A (en) | 1988-08-22 | 1991-03-19 | Kalt Medical Corporation | Transparent tracheostomy tube dressing |
EP0379416B1 (en) * | 1989-01-16 | 1995-03-08 | Roussel-Uclaf | Azabicycloheptene derivatives and their salts, process for their preparation, their use as medicaments and compositions containing them |
GB8906100D0 (en) | 1989-03-16 | 1989-04-26 | Smith & Nephew | Laminates |
US5261893A (en) | 1989-04-03 | 1993-11-16 | Zamierowski David S | Fastening system and method |
US5100396A (en) * | 1989-04-03 | 1992-03-31 | Zamierowski David S | Fluidic connection system and method |
US5527293A (en) * | 1989-04-03 | 1996-06-18 | Kinetic Concepts, Inc. | Fastening system and method |
US4969880A (en) | 1989-04-03 | 1990-11-13 | Zamierowski David S | Wound dressing and treatment method |
US5086764A (en) * | 1989-04-13 | 1992-02-11 | Thomas Gilman | Absorbent dressing |
US5358494A (en) * | 1989-07-11 | 1994-10-25 | Svedman Paul | Irrigation dressing |
JP2719671B2 (en) * | 1989-07-11 | 1998-02-25 | 日本ゼオン株式会社 | Wound dressing |
US5232453A (en) * | 1989-07-14 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Catheter holder |
GB2235877A (en) | 1989-09-18 | 1991-03-20 | Antonio Talluri | Closed wound suction apparatus |
US5134994A (en) * | 1990-02-12 | 1992-08-04 | Say Sam L | Field aspirator in a soft pack with externally mounted container |
US5092858A (en) * | 1990-03-20 | 1992-03-03 | Becton, Dickinson And Company | Liquid gelling agent distributor device |
JP2941918B2 (en) | 1990-09-19 | 1999-08-30 | テルモ株式会社 | Weighing device |
US5149331A (en) * | 1991-05-03 | 1992-09-22 | Ariel Ferdman | Method and device for wound closure |
US5278100A (en) * | 1991-11-08 | 1994-01-11 | Micron Technology, Inc. | Chemical vapor deposition technique for depositing titanium silicide on semiconductor wafers |
US5636643A (en) * | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
US5645081A (en) * | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
US5279550A (en) * | 1991-12-19 | 1994-01-18 | Gish Biomedical, Inc. | Orthopedic autotransfusion system |
US5167613A (en) | 1992-03-23 | 1992-12-01 | The Kendall Company | Composite vented wound dressing |
FR2690617B1 (en) * | 1992-04-29 | 1994-06-24 | Cbh Textile | TRANSPARENT ADHESIVE DRESSING. |
DE4306478A1 (en) | 1993-03-02 | 1994-09-08 | Wolfgang Dr Wagner | Drainage device, in particular pleural drainage device, and drainage method |
US5342376A (en) * | 1993-05-03 | 1994-08-30 | Dermagraphics, Inc. | Inserting device for a barbed tissue connector |
US6241747B1 (en) * | 1993-05-03 | 2001-06-05 | Quill Medical, Inc. | Barbed Bodily tissue connector |
US5344415A (en) * | 1993-06-15 | 1994-09-06 | Deroyal Industries, Inc. | Sterile system for dressing vascular access site |
US5437651A (en) * | 1993-09-01 | 1995-08-01 | Research Medical, Inc. | Medical suction apparatus |
US5549584A (en) * | 1994-02-14 | 1996-08-27 | The Kendall Company | Apparatus for removing fluid from a wound |
US5556375A (en) * | 1994-06-16 | 1996-09-17 | Hercules Incorporated | Wound dressing having a fenestrated base layer |
US5607388A (en) * | 1994-06-16 | 1997-03-04 | Hercules Incorporated | Multi-purpose wound dressing |
US5664270A (en) | 1994-07-19 | 1997-09-09 | Kinetic Concepts, Inc. | Patient interface system |
JP3687794B2 (en) | 1994-08-22 | 2005-08-24 | キネティック コンセプツ インコーポレイテッド | Wound drainage technology |
DE29504378U1 (en) | 1995-03-15 | 1995-09-14 | Mtg Medizinisch Tech Geraeteba | Electronically controlled low-vacuum pump for chest and wound drainage |
US8801681B2 (en) * | 1995-09-05 | 2014-08-12 | Argentum Medical, Llc | Medical device |
GB9523253D0 (en) | 1995-11-14 | 1996-01-17 | Mediscus Prod Ltd | Portable wound treatment apparatus |
US6135116A (en) * | 1997-07-28 | 2000-10-24 | Kci Licensing, Inc. | Therapeutic method for treating ulcers |
GB9719520D0 (en) | 1997-09-12 | 1997-11-19 | Kci Medical Ltd | Surgical drape and suction heads for wound treatment |
AU755496B2 (en) | 1997-09-12 | 2002-12-12 | Kci Licensing, Inc. | Surgical drape and suction head for wound treatment |
US6503527B1 (en) * | 1997-11-17 | 2003-01-07 | Haemacure Corporation | Fibrin sealants or adhesives comprising a hyaluronic acid derivative material |
US6071267A (en) * | 1998-02-06 | 2000-06-06 | Kinetic Concepts, Inc. | Medical patient fluid management interface system and method |
US6488643B1 (en) | 1998-10-08 | 2002-12-03 | Kci Licensing, Inc. | Wound healing foot wrap |
US6287316B1 (en) * | 1999-03-26 | 2001-09-11 | Ethicon, Inc. | Knitted surgical mesh |
US6856821B2 (en) * | 2000-05-26 | 2005-02-15 | Kci Licensing, Inc. | System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure |
US7799004B2 (en) * | 2001-03-05 | 2010-09-21 | Kci Licensing, Inc. | Negative pressure wound treatment apparatus and infection identification system and method |
US6991643B2 (en) * | 2000-12-20 | 2006-01-31 | Usgi Medical Inc. | Multi-barbed device for retaining tissue in apposition and methods of use |
US6423818B1 (en) * | 1999-07-30 | 2002-07-23 | Takehisa Matsuda | Coumarin endcapped absorbable polymers |
JP2001190597A (en) * | 2000-01-06 | 2001-07-17 | Uni Charm Corp | Hydrolyzable absorbent article |
TR200401397T4 (en) | 2000-02-24 | 2004-07-21 | Venetec International, Inc. | Universal catheter insertion system. |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US6540705B2 (en) * | 2001-02-22 | 2003-04-01 | Core Products International, Inc. | Ankle brace providing upper and lower ankle adjustment |
US6515075B1 (en) * | 2001-07-12 | 2003-02-04 | Kimberly-Clark Worldwide, Inc. | Films, fibers and articles of chemically modified polyethylene oxide compositions with improved environmental stability and method of making same |
GB2380135B (en) | 2001-09-27 | 2005-01-12 | Johnson & Johnson Medical Ltd | Therapeutic wound dressing |
US7846141B2 (en) * | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
US20070237812A1 (en) * | 2006-04-11 | 2007-10-11 | Tyco Healthcare Group | Multi-layer wound dressings |
US7976519B2 (en) | 2002-12-31 | 2011-07-12 | Kci Licensing, Inc. | Externally-applied patient interface system and method |
GB0508531D0 (en) * | 2005-04-27 | 2005-06-01 | Smith & Nephew | Sai with ultrasound |
CA2574927A1 (en) * | 2004-07-26 | 2006-02-09 | Kci Licensing, Inc. | Method for coating substrate with antimicrobial agent and product formed thereby |
US20060293630A1 (en) | 2005-06-22 | 2006-12-28 | Misonix Incorporated | Fluid containment apparatus for surgery and method of use |
BRPI0615765A2 (en) * | 2005-09-07 | 2011-05-24 | Tyco Healthcare | vacuum reservoir wound dressing |
GB0524027D0 (en) * | 2005-11-25 | 2006-01-04 | Smith & Nephew | Fibrous dressing |
DE202005019670U1 (en) * | 2005-12-14 | 2006-04-27 | Riesinger, Birgit | Wound treatment device with elastically deformable negative pressure generating element |
JP5149201B2 (en) * | 2006-01-23 | 2013-02-20 | ケーシーアイ ライセンシング インク | System and method for treating wounds using ultrasonic debridement |
SE0601536L (en) | 2006-07-11 | 2008-01-12 | Moelnlycke Health Care Ab | Coil connection |
US20080103462A1 (en) * | 2006-10-30 | 2008-05-01 | Stuart Wenzel | Wound healing patch with integral passive vacuum and electrostimulation |
US7943683B2 (en) * | 2006-12-01 | 2011-05-17 | Tepha, Inc. | Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers |
US9782300B2 (en) * | 2008-02-01 | 2017-10-10 | Kci Licensing, Inc. | Fiber-microsphere bioresorbable composite scaffold for wound healing |
US8357131B2 (en) * | 2008-09-18 | 2013-01-22 | Kci Licensing, Inc. | Laminar dressings, systems, and methods for applying reduced pressure at a tissue site |
-
2010
- 2010-06-25 US US12/823,958 patent/US8469936B2/en active Active
- 2010-06-28 CN CN201410640819.4A patent/CN104474596B/en not_active Expired - Fee Related
- 2010-06-28 CN CN201080031441.8A patent/CN102470200B/en not_active Expired - Fee Related
- 2010-06-28 EP EP14180083.9A patent/EP2801380B1/en not_active Not-in-force
- 2010-06-28 BR BR112012000869A patent/BR112012000869A2/en not_active IP Right Cessation
- 2010-06-28 AU AU2010273826A patent/AU2010273826B2/en not_active Ceased
- 2010-06-28 EP EP10731664.8A patent/EP2453943B1/en not_active Not-in-force
- 2010-06-28 EP EP16160737.9A patent/EP3058964B1/en active Active
- 2010-06-28 SG SG2012000295A patent/SG177489A1/en unknown
- 2010-06-28 CA CA2767982A patent/CA2767982C/en not_active Expired - Fee Related
- 2010-06-28 JP JP2012520653A patent/JP5561802B2/en not_active Expired - Fee Related
- 2010-06-28 WO PCT/US2010/040218 patent/WO2011008497A2/en active Application Filing
- 2010-07-08 TW TW099122531A patent/TW201113055A/en unknown
-
2013
- 2013-05-21 US US13/899,385 patent/US10149931B2/en active Active
-
2014
- 2014-06-05 JP JP2014116658A patent/JP5969539B2/en not_active Expired - Fee Related
-
2015
- 2015-05-26 AU AU2015202851A patent/AU2015202851B2/en not_active Ceased
-
2016
- 2016-07-07 JP JP2016134735A patent/JP6293824B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN104474596A (en) | 2015-04-01 |
CN102470200B (en) | 2014-12-10 |
US20110015595A1 (en) | 2011-01-20 |
SG177489A1 (en) | 2012-02-28 |
CN102470200A (en) | 2012-05-23 |
EP2801380B1 (en) | 2016-03-23 |
JP6293824B2 (en) | 2018-03-14 |
US8469936B2 (en) | 2013-06-25 |
JP2016190072A (en) | 2016-11-10 |
EP2453943B1 (en) | 2014-08-20 |
CA2767982C (en) | 2018-07-17 |
AU2010273826A1 (en) | 2012-02-02 |
BR112012000869A2 (en) | 2017-08-08 |
EP3058964B1 (en) | 2019-12-11 |
AU2015202851A1 (en) | 2015-06-18 |
WO2011008497A3 (en) | 2011-03-10 |
AU2015202851B2 (en) | 2017-05-25 |
WO2011008497A2 (en) | 2011-01-20 |
EP2801380A1 (en) | 2014-11-12 |
EP2453943A2 (en) | 2012-05-23 |
US10149931B2 (en) | 2018-12-11 |
AU2010273826B2 (en) | 2015-03-05 |
JP5561802B2 (en) | 2014-07-30 |
CN104474596B (en) | 2017-04-12 |
JP2014193395A (en) | 2014-10-09 |
JP2012533340A (en) | 2012-12-27 |
US20130317464A1 (en) | 2013-11-28 |
EP3058964A1 (en) | 2016-08-24 |
JP5969539B2 (en) | 2016-08-17 |
TW201113055A (en) | 2011-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015202851B2 (en) | Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers | |
US20190175416A1 (en) | Multi-Layer Dressings, Systems, And Methods For Applying Reduced Pressure At A Tissue Site | |
EP2470135B1 (en) | Re-epithelialization wound dressings and systems | |
AU2015200669B2 (en) | Multi-layer dressings, systems, and methods for applying reduced pressure at a tissue site |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20150626 |
|
MKLA | Lapsed |
Effective date: 20220301 |
|
MKLA | Lapsed |
Effective date: 20200831 |